Select other agents are encouraged as substitute brokers based upon administration challenges and/or adverse effect profile.  Zidovudine coupled with lamivudine is the choice NRTI backbone but is connected with far more hematologic toxicity. Lopinavir/ritonavir is another PI agent with founded security but displays increased gastrointestinal intol